<DOC>
	<DOC>NCT01392729</DOC>
	<brief_summary>This prospective observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with interferon alpha 2a in patients with previously untreated metastatic renal cell cancer. Data will be collected from each patient for up to 4 years.</brief_summary>
	<brief_title>An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Histologically confirmed metastatic renal cell cancer, clear cell type Eligible for treatment with Avastin and interferon alpha 2a according to local prescribing information Contraindications for Avastin or interferon alpha 2a treatment according to local Summary of Product Characteristics Known hypersensitivity to Avastin and/or interferon alpha 2a or any of its excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>